|
Back to Home » January 2021 News » Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day |
Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day |
January 20, 2021
STOCKHOLM, Jan. 20, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ - CALT) today announced it will provide information on the near-term clinical development plans for setanaxib in primary biliary cholangitis (PBC) and oncology. It will...
Source URL: https://www.prnewswire.com:443/news-releases/calliditas-announces-clinical-development-plan-for-setanaxib-and-comments-on-data-from-part-a-of-nefigard-study-at-todays-rd-day-301211542.html
|
|
|
|
